je.st
news
Tag: phase
RF Source provides true sinewave output with low phase noise.
2013-06-10 14:29:36| Industrial Newsroom - All News for Today
Designed using surface acoustic wave resonator technology, 2 GHz Model CRFS75-2000 features -134 dBc/Hz phase noise at 10 KHz offset and noise floor of -164 dBc/Hz. Source has no sub-harmonics; second harmonic is -20 dBc typical, and frequency accuracy is rated at ±150 ppm. With 5 V input voltage, device generates true sinewave with +5 dBm minimum output power. Housed in 0.75 x 0.75 in. SMT package, source is suited for ADCs, system clocks, avionics, and point-to-point radios. This story is related to the following:Signal Sources |
OCXO offers phase noise performance down to -172 dBc/Hz.
2013-06-10 14:29:36| Industrial Newsroom - All News for Today
Available at any frequency from 80–130 MHz, IQOV-200 Series delivers phase noise performance of -172 dBc/Hz at 100 kHz offset and -160 dBc/Hz at 1 kHz offset based on nominal oscillating frequency of 100 MHz. Oven Controlled Crystal Oscillator nominally operates from 12 V power supply and consumes 1 W of power at steady state. Drive capability is quoted at +6 dBm into 50 Ω. Housed in 36 x 27 mm IEC C008 Euro package, OCXO operates from -20 to 60°C with initial frequency stability of ±50 ppb. This story is related to the following:Crystal Oscillators |
Tags: offers
performance
phase
noise
New High Frequency OCXO From IQD Delivers Class Leading Phase Noise Performance Down To -172dBc/Hz
2013-06-06 02:59:21| rfglobalnet News Articles
Launching at IMS 2013, IQD’s new IQOV-200 series Oven Controlled Crystal Oscillator (OCXO) has been designed from the ground up to optimize low phase noise performance.
Tags: to
high
class
performance
Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation Of A Phase 1 Clinical Trial Of Anticancer Drug MRX34
2013-06-05 06:56:06| drugdiscoveryonline News Articles
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee, Mirna Therapeutics, has reported that they have initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer
Tags: reported
trial
drug
phase
Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin
2013-06-05 01:19:14| Logistics - Topix.net
Aeterna Zentaris Inc. today announced that final data for the Phase 1 portion of the ongoing Phase 1/2 trial with its lead oncology compound, zoptarelin doxorubicin , demonstrated the compound's promising anti-tumor activity in heavily pre-treated men with castration- and taxane-resistant prostate cancer.
Sites : [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] next »